Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA)
- 16 October 2018
- journal article
- research article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. 33 (4) , 195-200
Abstract
Background: The aim of this study was to determine carrier frequencies of the polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease (CHD) patients in Russian and Yakut ethnic groups. The association between the administration of higher doses of bisoprolol and metoprolol and the carriage of these polymorphic markers related to the decreased function of the haplotype of CYP2D6 was also studied.Methods: The study included 201 CHD patients (aged 66±8.7 years) receiving metoprolol in titrated dose (12.5–150 mg), bisoprolol (2.5–10 mg) or atenolol (50 mg). Ninety-three patients were Russian (30 men and 63 women), and 108 patients were Yakut (54 men and 54 women).Results: In genotyping CHD patients in the Russian and Yakut ethnic groups, there was no significant difference in the prevalence rate of the polymorphic markers G1846A (10.8 vs. 10.2; p=0.871) and C100T (16.1 vs. 16.2; p=1). In patients carrying the polymorphic marker G1846A, the dose of bisoprolol was established to be lower than that in the control group (p=0.0289).Conclusions: The carriage frequency of polymorphic markers, which theoretically should differ between Russians and Yakuts as representatives of two different races, in practice turned out to be the same.Keywords
This publication has 18 references indexed in Scilit:
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2013
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variationPharmacology & Therapeutics, 2013
- Human evolution in Siberia: from frozen bodies to ancient DNABMC Ecology and Evolution, 2010
- CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarctionEuropean Journal of Clinical Pharmacology, 2008
- Association ofCYP2D6andADRB1genes with hypotensive and antichronotropic action ofbetaxololin patients with arterial hypertensionFundamental & Clinical Pharmacology, 2007
- Influence of CYP2D6 Genotype on Metoprolol Plasma Concentration and β-Adrenergic Inhibition During Long-Term TreatmentJournal of Cardiovascular Pharmacology, 2005
- Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian populationEuropean Journal of Clinical Pharmacology, 2003
- Inheritance and Drug ResponseNew England Journal of Medicine, 2003
- Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics, 1997
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseNew England Journal of Medicine, 1982